phase trial cisplatin hyperton salin dose continu intraven infus patient advanc malign patient incur solid tumor phase trial fix dose high-dos cisplatin cddp hyperton salin dose infusion treatment level day leukopenia thrombocytopenia oral mucos dose-limit toxic nephrotox minim ototox peripher neuropathi rare mild patient group patient small number treatment cycl diarrhea dose-limit complet respons non-smal cell lung cancer sweat gland carcinoma major respons dose cddp set consecut day maximum dose mtd concurr infus recommend dosag phase II trial cddp consecut day cancer lung breast gastrointestin tract genitourinari tract reason target phase II studi 